サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1712514

がん治療の世界市場：2025年～2033年

Global Oncology Therapy Market - 2025-2033

出版日
ページ情報
英文 198 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
がん治療の世界市場：2025年～2033年
出版日: 2025年04月22日
発行: DataM Intelligence
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のがん治療の市場規模は、2024年に1,939億8,000万米ドルとなりました。同市場は、2033年には4,402億6,000万米ドルに達すると予測され、2025年から2033年の予測期間中に9.6％のCAGRで拡大する見込みです。

がん治療とは、がんを管理・治療するための治療や介入を指します。がん細胞の除去や制御、症状の緩和、患者のQOLの向上、そして可能であれば最終的には寛解や治癒の達成を目的とした幅広い治療戦略が含まれます。腫瘍学的治療は学際的であり、多くの場合、治療法の組み合わせ、個別化されたアプローチ、継続的なモニタリングが必要となります。

腫瘍学療法は、化学療法、免疫療法、標的療法、手術、放射線療法など、さまざまなアプローチによってがんを治療することを目的とした、幅広く発展的な分野です。これらの治療法は、がんの種類や病期に応じて、併用または単独で使用されます。個別化医療の進歩に伴い、がん治療の将来は、より少ない副作用でより高い有効性を提供する、より精密でオーダーメイドの治療にあります。

がんの有病率の上昇ががん治療市場の成長を大きく牽引しています。

がんは世界的に一般化しており、その罹患率の増加は効果的な治療や治療法に対する需要の高まりを生み出しています。がん患者の増加に伴い、化学療法、免疫療法、標的療法、放射線療法など、さまざまながん治療に対するニーズが高まっています。がんと診断される人が増え、治療を必要とする患者数が増加しているため、確立されたがん治療と新規のがん治療の両方に対する需要が高まっています。

例えば、米国立衛生研究所によると、がんは世界の主要な死因のひとつです。2022年には、世界中で約2,000万人の新規患者が発生し、970万人ががんに関連して死亡しました。2040年までには、年間の新規がん患者数は2,990万人に、がん関連死は1,530万人に増加すると予想されています。国際がん研究機関によると、2025年のがん罹患数は2,130万人に達し、2030年には2,410万人に達すると予測されています。

乳がんは世界で最も負担の大きいがんになりつつあり、罹患率と有病率は憂慮すべき上昇を見せています。例えば、国際がん研究機関の予測によると、2022年の230万人から2030年には270万人近くの乳がん罹患者が報告されると予想されています。診断される人が増えるにつれて、化学療法から高度な免疫療法に至るまで、効果的ながん治療に対する需要が高まっており、市場の継続的な拡大が確実なものとなっています。

腫瘍学的治療はがん治療に不可欠ですが、これらの治療に伴う副作用は、その普及と市場成長の妨げとなる可能性があります。副作用は軽度なものから重度なものまでさまざまで、患者のQOLに影響を及ぼすことが多く、治療の中止や変更につながることもあります。このような副作用の存在は、ヘルスケアプロバイダー、製薬会社、患者にとって課題となり、治療の意思決定に影響を及ぼし、市場の潜在的成長を制限します。

化学療法は最も一般的ながん治療の一つですが、急速に分裂する細胞に対して非選択的に作用するため、さまざまな毒性の副作用を伴います。化学療法はがん細胞を標的とするだけでなく、正常で健康な細胞にも影響を及ぼすため、重大な副作用を引き起こします。これらの副作用は治療の遅延や投与量の減少につながり、治療の全体的な有効性や患者のコンプライアンスに影響を及ぼす可能性があります。その結果、患者は代替療法を求めたり、処方された化学療法レジメンを完遂しないことを選択したりするようになり、市場全体の成長を妨げることになります。

免疫療法はメラノーマや肺がんなどの、がん治療において画期的ではありますが、免疫に関連した独特の有害事象を伴います。これらの副作用は、がん治療に対する免疫系の過剰反応から生じ、正常な組織や臓器に炎症を引き起こす可能性があります。標的療法は、従来の化学療法よりも正確ではありますが、影響を及ぼす標的分子に関連した特有の副作用があります。これらの治療法は、特定の遺伝子変異によって引き起こされるがんには非常に有効ですが、これらの分子標的の阻害に関連する副作用が、その使用を制限することがあります。

当レポートでは、世界のがん治療市場について調査し、市場の概要とともに、治療別、用途別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーとパイオニア
  • 最新の開発とブレークスルー
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向

第5章 がん治療市場（治療別）

  • 化学療法
  • 標的療法
  • 免疫療法
  • ホルモン療法
  • 放射線治療
  • その他

第6章 がん治療市場（用途別）

  • 乳がん
  • 肺がん
  • 血液がん
  • 前立腺がん
  • 大腸がん
  • 胃がん
  • 肝臓がん
  • 食道がん
  • 子宮頸がん
  • 卵巣がん
  • 膀胱がん
  • 頭頸部がん
  • 皮膚がん（メラノーマ）
  • 膵臓がん
  • 腎臓がん
  • その他

第7章 がん治療市場（エンドユーザー別）

  • 病院
  • がん研究センター
  • 専門クリニック
  • その他

第8章 がん治療市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要市場参入企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Amgen Inc.
    • 会社概要
    • 製品ポートフォリオ
    • 財務概要
    • 主な発展
    • SWOT分析
  • AstraZeneca
  • Bayer AG
  • Merck &Co., Inc.
  • Johnson &Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GSK plc
  • Eli Lilly and Company
  • Rigel Pharmaceuticals, Inc.

第11章 仮定と調査手法

第12章 付録

目次
Product Code: PH1793

The global oncology therapy market size reached US$ 193.98 billion in 2024 and is expected to reach US$ 440.26 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025-2033.

Oncology therapy refers to the medical treatments and interventions designed to manage and treat cancer. It encompasses a wide range of therapeutic strategies aimed at eliminating or controlling cancer cells, alleviating symptoms, enhancing the patient's quality of life, and ultimately achieving remission or a cure, where possible. Oncology therapy is multi-disciplinary and often requires a combination of treatments, personalized approaches, and ongoing monitoring.

Oncology therapy is a broad and evolving field that aims to treat cancer through various approaches, including chemotherapy, immunotherapy, targeted therapy, surgery, and radiation. These therapies can be used in combination or alone, depending on the type and stage of cancer. With advances in personalized medicine, the future of oncology therapy lies in more precise and tailored treatments that offer higher effectiveness with fewer side effects.

Market Dynamics: Drivers & Restraints

The rising prevalence of cancer is significantly driving the oncology therapy market growth

Cancer is becoming more common globally, and its increasing incidence is creating a heightened demand for effective treatments and therapies. As cancer cases rise, there is a growing need for various oncology therapies, such as chemotherapy, immunotherapy, targeted therapy, and radiation. More people are being diagnosed with cancer, increasing the patient pool requiring treatment, leading to greater demand for both established and novel cancer therapies.

For instance, according to the National Institutes of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. According to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.

Breast cancer is becoming the most burdensome cancer in the world, with an alarming rise in incidence and prevalence rate. For instance, according to the International Agency for Research on Cancer projections, nearly 2.7 million breast cancer incidence cases are expected to be reported in 2030, rising from 2.3 million in 2022. With more people being diagnosed, the demand for effective cancer treatments, ranging from chemotherapy to advanced immunotherapies, is intensifying, ensuring continued expansion in the market.

Adverse effects associated with various oncology therapies hamper market growth

While oncology therapies are essential for cancer treatment, adverse effects associated with these therapies can hamper their widespread adoption and market growth. The side effects, which range from mild to severe, often affect patients' quality of life and can lead to treatment discontinuation or modification. The presence of these adverse effects poses challenges for healthcare providers, pharmaceutical companies, and patients, influencing treatment decisions and limiting the market's potential growth.

Chemotherapy is one of the most common cancer treatments, but it is associated with a wide range of toxic side effects due to its non-selective action on rapidly dividing cells. It not only targets cancer cells but also affects normal, healthy cells, leading to significant side effects. These side effects can lead to treatment delays or dose reductions, which can impact the overall efficacy of the therapy and patient compliance. As a result, patients may seek alternative therapies or choose not to complete the prescribed chemotherapy regimen, hindering overall market growth.

Immunotherapy, though revolutionary in treating cancers like melanoma and lung cancer, comes with a unique set of immune-related adverse events. These adverse effects arise from the immune system's overreaction to cancer treatments, which can lead to inflammation in normal tissues and organs. Targeted therapies, while more precise than traditional chemotherapy, still have specific side effects related to the targeted molecules they affect. These therapies can be highly effective for cancers driven by specific genetic mutations, but side effects related to the inhibition of these molecular targets can limit their use.

Segment Analysis

The global oncology therapy market is segmented based on therapy, application, end-user, and region.

Application:

The breast cancer segment is expected to dominate the oncology therapy market with the highest market share

Breast cancer is the most common cancer in women worldwide. The global burden of breast cancer is substantial, and its increasing prevalence drives the demand for effective oncology therapies. For instance, according to the World Health Organization (WHO), in 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths globally, making it the most common cancer across both developed and developing countries.

The advancements in breast cancer treatments are a major driver of the segment's dominance. Over the last few decades, innovations such as targeted therapies, hormonal therapies, and immunotherapies have dramatically improved survival rates and quality of life for breast cancer patients. For instance, targeted therapies like Trastuzumab (Herceptin) have transformed the treatment of HER2-positive breast cancer, leading to improvements in survival for patients.

Novel product launches by major market players in the field of breast cancer are boosting the segment. For instance, in January 2024, AstraZeneca India Pharma Ltd., a science-led biopharmaceutical company, officially launched Trastuzumab deruxtecan, a therapy tailored for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer for those who have previously received an anti-HER2 regimen. Developed in collaboration with Daiichi Sankyo, Trastuzumab deruxtecan is a specifically engineered HER2-directed antibody drug conjugate (ADC).

Geographical Analysis

North America is expected to hold a significant position in the global oncology therapy market with the highest market share

The oncology therapy market in the North America region is expected to grow owing to the strong presence of major market players, the rising prevalence of cancers, increasing research activities, rising awareness about cancer, rising clinical studies, and well-established healthcare infrastructure. The prevalence of cancer in the United States is continuously rising, which further increases the demand for various oncology therapies. Factors such as aging populations, lifestyle changes, and the prevalence of risk factors like obesity and smoking are driving the demand for improved treatments.

Moreover, the presence of major market players in the region launching various oncology therapies, along with FDA approvals, further accelerates the market growth in the region. For instance, in April 2024, Johnson & Johnson cleared the U.S. Food and Drug Administration (FDA) approval for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. With this approval, CARVYKTI becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Additionally, in May 2024, Amgen announced that the U.S. Food and Drug Administration (FDA) approved IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Competitive Landscape

Top companies in the oncology therapy market include Amgen Inc., AstraZeneca, Bayer AG, Merck & Co., Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, GSK plc, Eli Lilly and Company, Rigel Pharmaceuticals, Inc., and others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global oncology therapy market report delivers a detailed analysis with 62 key tables, more than 69 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Therapy
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Cancer
      • 3.1.1.2. Rising Adoption of Combination Therapies
    • 3.1.2. Restraints
      • 3.1.2.1. Adverse Effects Associated with Various Oncology Therapies
      • 3.1.2.2. High Cost of Treatment for Oncology Therapy
    • 3.1.3. Opportunity
      • 3.1.3.1. Personalized and Precision Oncology
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with the Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Patent Analysis
  • 4.6. SWOT Analysis
  • 4.7. Unmet Needs and Gaps
  • 4.8. Recommended Strategies for Market Entry and Expansion
  • 4.9. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.10. Pricing Analysis and Price Dynamics

5. Oncology Therapy Market, By Therapy

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 5.1.2. Market Attractiveness Index, By Therapy
  • 5.2. Chemotherapy*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Alkylating Agents
    • 5.2.4. Antimetabolites
    • 5.2.5. Anti-tumor Antibiotics
    • 5.2.6. Topoisomerase Inhibitors
    • 5.2.7. Others
  • 5.3. Targeted Therapy
    • 5.3.1. Monoclonal Antibodies
    • 5.3.2. Small Molecule Inhibitors
  • 5.4. Immunotherapy
    • 5.4.1. Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
    • 5.4.2. CAR-T Cell Therapy
    • 5.4.3. Cancer Vaccines
    • 5.4.4. Cytokines
    • 5.4.5. Others
  • 5.5. Hormonal Therapy
    • 5.5.1. Anti-estrogens
    • 5.5.2. Aromatase Inhibitors
    • 5.5.3. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists/Antagonists
    • 5.5.4. Others
  • 5.6. Radiation Therapy
  • 5.7. Others

6. Oncology Therapy Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Breast Cancer*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Lung Cancer
  • 6.4. Blood Cancer
  • 6.5. Prostate Cancer
  • 6.6. Colorectal Cancer
  • 6.7. Stomach Cancer
  • 6.8. Liver Cancer
  • 6.9. Esophageal Cancer
  • 6.10. Cervical Cancer
  • 6.11. Ovarian Cancer
  • 6.12. Bladder Cancer
  • 6.13. Head and Neck Cancer
  • 6.14. Skin Cancer (Melanoma)
  • 6.15. Pancreatic Cancer
  • 6.16. Kidney Cancer
  • 6.17. Others

7. Oncology Therapy Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cancer Research Centers
  • 7.4. Specialty Clinics
  • 7.5. Others

8. Oncology Therapy Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. China
      • 8.4.6.2. India
      • 8.4.6.3. Japan
      • 8.4.6.4. South Korea
      • 8.4.6.5. Rest of Asia-Pacific
  • 8.5. South America
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. Brazil
      • 8.5.6.2. Argentina
      • 8.5.6.3. Rest of South America
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Amgen Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. AstraZeneca
  • 10.3. Bayer AG
  • 10.4. Merck & Co., Inc.
  • 10.5. Johnson & Johnson Services, Inc.
  • 10.6. F. Hoffmann-La Roche Ltd
  • 10.7. Novartis AG
  • 10.8. GSK plc
  • 10.9. Eli Lilly and Company
  • 10.10. Rigel Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us